KMDA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	10 363.00
Average Volume	22 206.00
Market Cap	298.87M
EPS	$0 ( 2024-03-06 )
Next earnings date	( $0.0600 ) 2024-05-22
Last Dividend	$0.00600 ( 2013-06-13 )
Next Dividend	$0 ( N/A )
P/E	34.67
ATR14	$0.0360 (0.70%)

Kamada Ltd Correlation

10 Most Positive Correlations
GAINL	0.895
RMRM	0.88

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kamada Ltd Financials

Annual	2023
Revenue:	$144.76M
Gross Profit:	$52.59M (36.33 %)
EPS:	$0.170

Q4	2023
Revenue:	$38.35M
Gross Profit:	$15.17M (39.56 %)
EPS:	$0.0926

Q3	2023
Revenue:	$37.93M
Gross Profit:	$14.80M (39.02 %)
EPS:	$0.0686

Q2	2023
Revenue:	$37.44M
Gross Profit:	$14.44M (38.55 %)
EPS:	$0.0397

Financial Reports:

No articles found.

Kamada Ltd Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Kamada Ltd Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.03 - good (90.33%) | Divividend Growth Potential Score: 2.36 - No dividend growth expected in the near future

Information

First Dividend	$0.00600	2013-06-13
Last Dividend	$0.00600	2013-06-13
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.00600	--
Avg. Dividend % Per Year	0.00%	--
Score	1.72	--
Div. Sustainability Score	9.03
Div.Growth Potential Score	2.36
Div. Directional Score	5.70	--

Next Divdend (Est)
(2024-04-25)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

1.72

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2013	$0.00600	0.06%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0574	1.500	8.85	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0235	1.200	9.22	10.00	[0 - 0.3]
returnOnEquityTTM	0.0398	1.500	-0.669	-1.003	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.43	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.554	0.800	5.56	4.45	[0.8 - 2.5]
cashRatioTTM	1.122	1.500	4.88	7.32	[0.2 - 2]
debtRatioTTM	0.0250	-1.500	9.58	-10.00	[0 - 0.6]
interestCoverageTTM	6.53	1.000	8.69	8.69	[3 - 30]
operatingCashFlowPerShareTTM	0.0760	2.00	9.97	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.0278	2.00	-0.0139	-0.0278	[0 - 20]
debtEquityRatioTTM	0.0364	-1.500	9.85	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.389	1.000	6.84	6.84	[0.2 - 0.8]
operatingProfitMarginTTM	0.0587	1.000	-0.827	-0.827	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.496	1.000	8.36	8.36	[0.2 - 2]
assetTurnoverTTM	0.410	0.800	-0.598	-0.478	[0.5 - 2]
Total Score				9.03

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	35.94	1.000	6.47	0	[1 - 100]
returnOnEquityTTM	0.0398	2.50	-0.430	-1.003	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0278	2.00	-0.00928	-0.0278	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0760	2.00	9.97	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.636	1.500	9.09	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0302	1.000	-1.744	0	[0.1 - 0.5]
Total Score				2.36

Kamada Ltd

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.